All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @its.luisanna on TikTok · 24s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @its.luisanna's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00So I contemplated not posting this because it feels like very slight progress compared to others especially on TikTok
  2. 0:06But my progress makes sense for me. It makes sense for the plan I'm on and for my body
  3. 0:11So I'm going to post it anyway in eight weeks
  4. 0:14I have lost over 13 pounds and eight inches and it's not fast
  5. 0:19But it's consistent and that's exactly what I want. So here it is

@its.luisanna's Zepbound progress claims, fact-checked

Luisanna | Fitness & Wellness

TikTok creator

33.7K viewsWatch on TikTok

Quick answer

Tirzepatide (Zepbound) is a dual GIP and GLP-1 receptor agonist approved by the FDA for chronic weight management in adults with obesity or overweight with a weight-related comorbidity. The creator reported 13 pounds and 8 inches of loss over 8 weeks, which falls within the plausible range observed in early-phase tirzepatide treatment in the SURMOUNT-1 trial. Individual response varies by dose, starting weight, and metabolic factors, and 8 weeks represents an early snapshot of a treatment course typically evaluated over 52 to 72 weeks.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded TirzepatideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Tirzepatide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @its.luisanna's Zepbound progress claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Tirzepatide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this tirzepatide video claims cluster

Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@its.luisanna's Zepbound progress claims, fact-checked" from Luisanna | Fitness & Wellness. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tirzepatide (Zepbound) is a dual GIP and GLP-1 receptor agonist approved by the FDA for chronic weight management in adults with obesity or overweight with a weight-related comorbidity.

The reason this review is not generic is the source wording and the canonical claim label "glp1 2 month progress ft my crotch goblin zepbound glp1." In this clip, the useful excerpt is: "So I contemplated not posting this because it feels like very slight progress compared to others especially on TikTok But my progress makes sense for me." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

The SURMOUNT-1 trial (Jastreboff et al.
People who land here are usually comparing the Compounded Tirzepatide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Tirzepatide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Tirzepatide (Zepbound) is a dual GIP and GLP-1 receptor agonist approved by the FDA for chronic weight management in adults with obesity or overweight with a weight-related comorbidity.

FormBlends verdict

Compounded Tirzepatide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Tirzepatide (Zepbound) is a dual GIP and GLP-1 receptor agonist approved by the FDA for chronic weight management in adults with obesity or overweight with a weight-related comorbidity. The creator reported 13 pounds and 8 inches of loss over 8 weeks, which falls within the plausible range observed in early-phase tirzepatide treatment in the SURMOUNT-1 trial. Individual response varies by dose, starting weight, and metabolic factors, and 8 weeks represents an early snapshot of a treatment course typically evaluated over 52 to 72 weeks.
  • 13 pounds in 8 weeks is approximately 1.6 lbs per week, within the clinically sustainable range of 1-2 lbs per week during active GLP-1 treatment.
  • The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed average tirzepatide weight loss of 20.9% over 72 weeks, meaning 8-week snapshots are early and incomplete data.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.

Review Compounded Tirzepatide

What You'll Learn

  • 13 pounds in 8 weeks is approximately 1.6 lbs per week, within the clinically sustainable range of 1-2 lbs per week during active GLP-1 treatment.
  • The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed average tirzepatide weight loss of 20.9% over 72 weeks, meaning 8-week snapshots are early and incomplete data.
  • The FDA considers 5% body weight loss the threshold for an effective weight intervention. Depending on starting weight, 13 lbs in 8 weeks may already meet or exceed that bar.
  • TikTok weight loss content overrepresents outlier results. A 2023 PLOS ONE study found health content on the platform is subject to significant selection bias toward dramatic outcomes.
  • Inch loss and scale weight are separate metrics. Body composition changes, including fat loss with muscle retention, can produce meaningful inch reduction before scale weight drops significantly.
  • Tirzepatide works over a long arc. Clinical trials run 52-72 weeks. Judging a GLP-1 course at 8 weeks is like reviewing a book after the first chapter.
  • Her decision to frame results as personal rather than universal is one of the more responsible things a GLP-1 creator can do on social media, and it is not common enough.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @its.luisanna actually say?

She posted a two-month Zepbound progress update and almost didn't. Her hesitation is worth noting: she felt her results looked "slight" compared to what she sees on TikTok. What she actually reported was losing "over 13 pounds and eight inches" in eight weeks, and she framed it not as a failure but as progress that "makes sense" for her body and her plan. No wild claims. No supplement plugs. Just numbers and context.

That kind of restraint is genuinely rare in GLP-1 content. She didn't promise anyone the same results, didn't attribute the loss to anything beyond being on a plan, and didn't dramatize the timeline. The video is essentially a personal data point delivered with unusual honesty about how social media distorts expectations.

Does the science back this up?

Yes, her results are consistent with published tirzepatide data, though she is tracking at the lower end of what clinical trials observed. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found participants lost an average of 20.9% of body weight over 72 weeks on the highest dose of tirzepatide. Early-phase loss tends to be faster, but it varies substantially by individual.

Thirteen pounds in eight weeks works out to roughly 1.6 pounds per week. That sits within the range dietitians and obesity medicine physicians typically consider sustainable, roughly one to two pounds per week during active treatment. Faster early loss is common on GLP-1 medications, but the people posting dramatic six-week transformations are often outliers, not the average patient. Her framing of consistent over fast is actually more aligned with how clinical weight loss is measured in trials than most TikTok content acknowledges.

What did they get wrong (or right)?

She got more right than wrong here. The claim that her progress "makes sense for my body" is not medically specific, but it is not wrong either. Tirzepatide response genuinely does vary by dose, metabolic baseline, starting weight, and adherence, so individual variation is real and documented.

The one thing worth flagging is not something she said incorrectly, it is something she left implicit. Comparing yourself to TikTok weight loss content is a genuinely bad benchmark. A 2023 analysis published in PLOS ONE (Simms-Cendan et al.) found that health content on TikTok systematically overrepresents extreme outcomes. People who lose 30 pounds in six weeks post. People who lose 13 pounds in eight weeks often don't, or they feel like they have to apologize when they do. Luisanna almost didn't post this. That tells you something about the information environment she and her audience are swimming in.

What should you actually know?

GLP-1 and dual GIP/GLP-1 medications like tirzepatide (Zepbound) are not magic, and the results you see on social media are not representative samples. The SURMOUNT-1 trial used a 72-week treatment window. Two months is a fraction of that. Weight loss on these medications tends to plateau and then continue in waves, and the trajectory at eight weeks tells you very little about where someone ends up at 52 weeks.

Thirteen pounds in eight weeks is a clinically meaningful result. For context, the FDA's threshold for a weight loss intervention to be considered effective is 5% of body weight loss. Depending on her starting weight, she may already be near or past that threshold in two months. Inch loss, which she also reported, is a separate and valid metric because body composition shifts can precede scale movement. She is not behind. She is on a reasonable curve.

  • Response to tirzepatide varies significantly by dose. Titration schedules affect early outcomes.
  • Comparing eight-week results to peer timelines on TikTok introduces significant selection bias.
  • Consistent loss over time predicts better long-term outcomes than rapid early loss followed by plateau.

Bottom line

This is one of the more honest GLP-1 progress posts you will find on TikTok. She reported real numbers, contextualized them accurately, and pushed back against the unrealistic comparison culture baked into the platform. The science supports her results as plausible and meaningful. The main thing to carry away is that her instinct to post anyway, despite feeling like her progress was "slight," is the right instinct. Her numbers are not slight. The benchmark is broken.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Luisanna | Fitness & Wellness · TikTok creator

33.7K views on this video

2 month progress ft. my crotch goblin 🫶🏽 #zepbound #glp1 #weightloss

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about 13 pounds in 8 weeks?

13 pounds in 8 weeks is approximately 1.6 lbs per week, within the clinically sustainable range of 1-2 lbs per week during active GLP-1 treatment.

What does the video say about the surmount-1 trial (jastreboff et al., 2022, nejm) showed average?

The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed average tirzepatide weight loss of 20.9% over 72 weeks, meaning 8-week snapshots are early and incomplete data.

What does the video say about the fda considers 5% body weight loss the threshold for?

The FDA considers 5% body weight loss the threshold for an effective weight intervention. Depending on starting weight, 13 lbs in 8 weeks may already meet or exceed that bar.

What does the video say about tiktok weight loss content overrepresents outlier results. a 2023 plos?

TikTok weight loss content overrepresents outlier results. A 2023 PLOS ONE study found health content on the platform is subject to significant selection bias toward dramatic outcomes.

What does the video say about inch loss?

Inch loss and scale weight are separate metrics. Body composition changes, including fat loss with muscle retention, can produce meaningful inch reduction before scale weight drops significantly.

What does the video say about tirzepatide works over a long arc. clinical trials run 52-72?

Tirzepatide works over a long arc. Clinical trials run 52-72 weeks. Judging a GLP-1 course at 8 weeks is like reviewing a book after the first chapter.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Luisanna | Fitness & Wellness, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.